Plus Therapeutics, Inc. (PSTV) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -202.05%, forward earnings yield 79.37%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -8.9 | 0.25 | 17.82 | 17.21 | - |
| 2017 | 0.0 | 0.00 | 0.07 | 0.15 | - |
| 2018 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2019 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2020 | 0.0 | 0.00 | 0.00 | 0.03 | - |
| 2021 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2022 | 0.0 | 0.00 | 0.00 | 0.04 | - |
| 2023 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2024 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2025 | -1.8 | 0.02 | 9.98 | 7.65 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-9,600.00 | $11.38M | $-22.05M | -193.7% |
| 2017 | $-5,253.82 | $6.41M | $-22.69M | -353.9% |
| 2018 | $-1,304.70 | $2.98M | $-12.63M | -423.5% |
| 2019 | $-138.10 | $7M | $-10.89M | -155.6% |
| 2020 | $-27.90 | $303K | $-8.24M | -2719.8% |
| 2021 | $-17.78 | $0.00 | $-13.4M | - |
| 2022 | $-11.55 | $224K | $-20.28M | -9051.3% |
| 2023 | $-4.24 | $4.91M | $-13.32M | -271% |
| 2024 | $-2.34 | $5.82M | $-12.98M | -222.8% |
| 2025 | $-0.29 | $5.21M | $-22.39M | -429.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.14 | $-0.14 – $-0.13 | $6.23M | $5.29M – $7.17M | 3 |
| 2027 | $-0.08 | $-0.10 – $-0.06 | $23.64M | $18.9M – $28.63M | 2 |
| 2028 | $-0.03 | $-0.03 – $-0.02 | $47.73M | $47.73M – $47.73M | 4 |
| 2029 | $0.22 | $0.16 – $0.28 | $133.11M | $106.39M – $161.17M | 2 |
| 2030 | $0.37 | $0.27 – $0.47 | $184.95M | $147.82M – $223.94M | 2 |
